Slide 1: Share Offering Summary
1 OTCQB: REPCF TSXV: RP Share Offering Summary FRA:P6P2 May 2019
Slide 2: Safe Harbour Statements
Safe Harbour Statements 2 As used in this investor presentation (the “Presentation”), the terms “we”, “us”, “ours”, The factors and assumptions included, but are not limited to,: “RepliCel” and “Company” mean ReliCel Life Sciences Inc., a British Columbia, Canada corporation, and our wholly-owned su
Slide 3: Today's Innovations. Tomorrow's Products.
The Board is focused on transitioning RepliCel from a blue-sky biotech to a commercial company with multiple products* on the market. By 2020: RCI-02 Europe**, Hong Kong Today’s Innovations. By 2023: Tomorrow’s Products. RCI-02 global RCS-01 Japan RCT-01 Japan * There is also the possibility Shiseid
Slide 4: Today's Innovation. Tomorrow's Products.
Current OTCQB: REPCF TSXV: RP FRA:P6P2 (as of May 2019) Current market cap. (approx.) ~$9.5M Total money raised through equity to- ~$33.6M date Total revenue to-date $4.24M (initial licensing payments Today’s Innovation. from Shiseido & YOFOTO) Tomorrow’s Products. Target date for initial product sa
Slide 5: Strategic Plan (Development)
Strategic Plan (Development) By end of 2020: • 2 clinical trials ongoing in Japan; • 2 clinical trials ongoing in China (financed by YOFOTO); • new clinical data announced from the RCH-01 clinical Today’s Innovation. research in Japan (financed by Shiseido); Tomorrow’s Products. • new clinical data
Slide 6: Strategic Plan (Commercial)
Strategic Plan (Commercial) By 2023, RepliCel aims to have 3 products* (two biologics and one device) on the market. Achieving this target will be dependent on the following: 1. $2.5M in an equity raise now ** (mid-2019) 2. $1M from warrant exercise before Nov 2020 ($5.5M between May 2019 and Dec 20
Slide 7: Preferred Share Placement
Preferred Share Placement Financing Need: • $5.5M required over 3.5 years plus a new Japanese partnership in place by mid-2020 to get to multiple commercial products by 2023. • Current plan is for $2.5M to come through equity raise, $1M to come through warrant exercise (by Nov 2020), $2M to come thr
Slide 8: Preferred Share Placement Offering Terms
Preferred Share Placement Offering Terms RepliCel Board of Directors has authorized the creation of a new class of shares which will be preferred shares designated as Class A Preference Shares (“Preferred Shares”). The Board has also authorized an offering of the newly created Preferred Shares on th
Slide 9: Attributes of this Preferred Share Offering
Preferred Share Placement Attributes of this Preferred Share Offering • Offers a dividend (payable in cash at fixed rate or in common shares) • Maximum term of five years before exit at fixed price or conversion into common shares • Can convert at any time and exercise liquidity • If you are already
Slide 10: Preferred Share Offering – Risk Profile
Preferred Share Placement Preferred Share Offering – Risk Profile • Preferred Shares will rank higher than common shares in in any liquidation scenario in that preferred shareholders are made whole, before common shareholders receive any compensation in the event of a wind-up, dissolution or bankrup
Slide 11: Preferred Share Placement: Anticipated Return
Preferred Share Placement: Anticipated Return Return and Equity Attributes • Shareholders will earn a quarterly 7% dividend • RepliCel is obligated to buy the shares at $1.50 within five years after the issue date (in 2024) (a 100% return on initial investment) • Shareholders can convert each prefer
Slide 12: Preferred Share Placement: Value Creation
Preferred Share Placement: Value Creation RepliCel and its partners have developed a strategic plan to deliver the following by 2023: • The dermal injector on the market in Europe, Hong Kong, Japan and other markets • The tendon regeneration product on the market in Japan • The skin rejuvenation pro
Slide 13: Planned 2019 Milestones
Planned 2019 Milestones Quarter Milestone Q2 UBC reports initial findings to RepliCel from its genetic marker profiling study Q3 YOFOTO to submit application to regulatory authorities for clinical studies of RCT-01 and RCS-01 in China Regulatory reviews with PMDA in Japan commenced seeking approval
Slide 14: Planned 2020 Milestones
Planned 2020 Milestones Quarter Milestone Launch of RCS-01 clinical trial in China Q1 CE Mark granted on RCI-02 device; CE Mark granted on needle head for device; CE Mark granted for assembled syringe unit for use with the device Q2 Payment of first milestone payment by YOFOTO Launch of RCI-01 devic
Slide 15: Planned 2021 Milestones
Planned 2021 Milestones Quarter Milestone Q1 Broader European market launch of RCI-02 device and consumables Q2 First-year anniversary of RCI-01 device and consumables being on the market Q3 Clinical data from ph 2 clinical trial of RCS-01 in China Second YOFOTO milestone payment (completion of ph 2
Slide 16: Planned 2022 Milestones
Planned 2022 Milestones Month Milestone Q1 Market launch of RCI-02 device and consumables in Japan* Q2 Data from clinical trial of RCT in Japan Market launch of RCS-01 in Japan * Q4 PMDA conditional marketing approval for RCT in Japan * * To be funded by Japanese partner not yet secured or additiona
Slide 17: Planned 2023 Milestones
Planned 2023 Milestones Month Milestone Reimbursement pricing set for RCT-01 in Japan Q1 Market launch of RCT-01 in Japan * * To be funded by Japanese partner not yet secured or additional funds raised
Slide 18: RCI-02 Production Gantt Chart
RCI-02 Production Gantt Chart Sept 2019 Apr 2020 Prototype Production Release for Sale
Slide 19: Regulatory Review of NBDS Products - Gantt Chart for Japan
Regulatory Review of NBDS Products - Gantt Chart for Japan Approvals Needed to Commence Clinical Trials in Japan for RCT-01 and RCS-01
Slide 20: Potential Japanese Deal for RCT & RCS
Potential Japanese Deal for RCT & RCS RepliCel is leveraging its own existing footprint in Japan • Replicel was one of the first foreign regenerative medicine companies to have a Japanese partnership • RepliCel was one of the first foreign regenerative medicine companies to initiate the consultation
Slide 21: Potential Japanese Deal for RCT & RCS
Potential Japanese Deal for RCT & RCS Recent partnerships in the sector • A survey of regenerative medicine licensing partnerships done in Japan over the past 5 years indicate a range of upfront payments of $1-50M for total deal values of $4-600M under a wide variety of deal structures involving pro
Slide 22: Three clinical applications, two biologics, one innovative delivery platform
Three clinical applications, two biologics, one innovative delivery platform SPORTS MEDICINE AESTHETICS and AESTHETIC MEDICINE RCT-01: RCS-01: NBDS Fibroblast NBDS Fibroblast Therapy Therapy for Chronic for Aging and Sun- RCI-02: Tendinosis Damaged Skin Dermal Injector Device (Achilles Tendon, √ pha
Slide 23: Partnership in Greater China
Partnership in Greater China co-development and licensed commercialization in Asia SPORTS MEDICINE AESTHETICS and AESTHETIC MEDICINE RCT-01: RCS-01: RCI-02: NBDS Fibroblast NBDS Fibroblast Therapy Dermal Injector Therapy for Chronic for Aging and Sun- Device Tendinosis Damaged Skin (cells, toxins, f
Slide 24: Pattern Baldness
21 Partnership in Asia co-development and licensed commercialization in Asia Pattern Baldness RCH-01: DSC Cell Therapy for Androgenetic Alopecia (male and female pattern hair loss) √ phase 1 data (Europe) √ Clinical data pending (Japan)
Slide 25: RepliCel History
RepliCel History TRICHOSCIENCE REPLICEL LIFE SCIENCES MCELWEE & HOFFMANN E INNOVATIONS _ incorporated, merges with TrichoScience (sub) Initial discoveries published Incorporated & Newclastle Resources (OTC Listed) rr RCH-01 SHISIEDO LICENSE PHASE 1 DATA RCT-01 TSX.V RCH-01 exclusive license 6-month
Slide 26: RCT-01 Tendon Repair
RCT-01 Tendon Repair Successful phase 1 clinical trial Phase 2 clinical trial expected to commence completed (Canada) in 2020 in Republic of China (with RepliCel’s partner YOFOTO) Clinical trial expected to First product launch expected in Japan in commence in 2020 in Japan 2023. (with RepliCel part
Slide 27: RCS-01 Dermal Rejuvenation
RCS - 01 Dermal Rejuvenation Successful phase 1 clinical trial Phase 2 clinical trial expected to commence completed (Germany). in 2020 in Republic of China. (with RepliCel’s partner YOFOTO) Clinical trial expected to First product launch expected in Japan in commence in 2020 in Japan. 2022. (with R
Slide 28: RCH-01 Pattern Baldness (Continued)
RCH-01 Pattern Baldness (Continued) Successful phase 1 clinical trial Clinical research to be completed later this completed (Republic of Georgia). year in Japan funded by RepliCel partner Shiseido Company. Ongoing research being conducted First product launch may be in Japan by at the University of
Slide 29: RCI-02 - Dermal Injector
RCI-02 - Dermal Injector First functional prototypes built Commercial-grade prototypes expected Q3 and tested. 2019. Commercial partner* already in First product launch in Europe and Hong place in Hong Kong which accept Kong expected mid-2020. CE marks for medical devices. * RepliCel’s licensee YOFO
Slide 30: 2017 Milestones
2017 Milestones Month News February European Patents for its Innovative Dermal Injector Technologies February Closing of Brokered and Non-brokered Private Placement March Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints Successful RCT-01 Tendon Repair Clinical Trial Shows S
Slide 31: 2018 Milestones
2018 Milestones Month News Binding Term Sheet for strategic investment and partnership from YOFOTO in Greater January China May Revised binding term Sheet with YOFOTO July RepliCel and YOFOTO sign Investment and Licensing Agreements September RepliCel and YOFOTO obtain all approvals needed to close
Slide 32: Recent Strategic Transaction: Introduction to YOFOTO
RECENT STRATEGIC TRANSACTION Introduction to YOFOTO YOFOTO (China) Health Industry Co., Ltd was established in 2004 engaged in the consumer health industry innovation and marketing. YOFOTO has registered several hundred trademarks and dozens of patents. YOFOTO has 32 provincial branches in China and
Slide 33: Statutory Rights of Action for Purchasers Resident in Certain Provinces of Canada
STATUTORY RIGHTS OF ACTION FOR PURCHASERS RESIDENT IN CERTAIN PROVINCES OF CANADA This presentation may not be reproduced, further distributed or published in whole or in part by any other person. Neither this presentation nor any copy of it may be taken or transmitted into or distributed in any oth
Slide 34: Statutory Rights of Action for Purchasers Resident in Saskatchewan
Statutory Rights of Action for Purchasers Resident in Saskatchewan This presentation could constitute an offering memorandum under Saskatchewan laws. In the event that this presentation is an offering memorandum, you will have certain rights provided to you by The Securities Act (Saskatchewan) (the
Slide 35: Statutory Rights of Action for Purchasers Resident in Ontario
Statutory Rights of Action for Purchasers Resident in Ontario This presentation could constitute an offering memorandum under Ontario laws. In the event that this presentation is an offering memorandum, you will have certain rights provided to you by the Securities Act (Ontario) (the “Ontario Act”)
Slide 36: Contact
34 CONTACT R. Lee Buckler President & CEO 604.248.8693 lee@replicel.com OTCQB: REPCF TSXV: RP FRA:P6P2 VISIT US ON SOCIAL MEDIA